ClinicalTrials.gg
Active, not recruitingNCT00560651Updated Jun 18, 2026Results posted

German Corneal Cross Linking Register

An observational study in Keratoconus, sponsored by Suphi Taneri. Active, not recruiting at 2 sites in Germany. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Suphi Taneri · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
356
Sex
All
01

Study summary

Corneal Cross Linking is new treatment modality for patients with keratoconus. A keratoconus is characterized by progressive bulging and thinning of the eye's cornea. Keratoconus is a potentially severely sight impairing condition that may necessitate corneal transplantation in the progressive state.

Corneal Cross Linking is designed to

  • increase the cornea's mechanical stability
  • to stop progression of bulging and thinning of the cornea
  • to prevent the need for corneal transplantation

Corneal Cross Linking is performed by

  1. Applying Riboflavin (Vitamin B2) eye drops every 2 minutes for 30 minutes to the cornea
  2. Illuminating the cornea with UV-light

This register of Corneal Cross Linking procedures performed in Germany serves to

  • gather long-term results
  • detect rare complications and side-effects
  • evaluate the efficacy in a large number of patients
02

Conditions studied

  • Keratoconus

Keywords

  • keratoconus
  • cornea
  • cross linking
  • UV-light
  • riboflavin
03

In context

Keratoconus

313 studies on the registry are indexed under Keratoconus; 55 are open to participants now.

This study's enrollment of 356 is above the median of 130 across 97 observational studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

Suphi Taneri is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients treated with Corneal Cross Linking in Germany

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with keratokonus and treated with corneal cross Linking in Germany

Exclusion criteria

Exclusion Criteria:

  • Non-ectatic conditions
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
356 participants (actual)
Patient registry
No

Groups and cohorts

  • 1

    Cross linked eyes

    Procedure: CCL (Corneal Cross Linking)

Interventions

  • ProcedureCCL (Corneal Cross Linking)

    Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance

    Also known as: Collagen cross linking, Corneal collagen cross linking, CCL, 3C-L

06

What researchers measure

Primary outcomes

  1. Visual Acuity

    Corrected Visual Acuity after crosslinking at the latest follow up examination

    Time frame: 172 to 3396 days

  2. Postoperative K Max

    K max after Crosslinking

    Time frame: 172 to 3396 days

  3. Sphere

    Sphere values after crosslinking at lastest-follow-up

    Time frame: 172 to 3396 days

  4. Cylinder

    Refractive cylinder after Crosslinking at latest follow-up

    Time frame: 172 to 3396 days

Other outcomes

  1. Endothelial Cell Density

    Endothelial cell density after Crosslinking at latest follow-up

    Time frame: 172 to 3396 days

07

Results

Posted Jun 18, 2026

Participant flow

All eyes included with corneal crosslinking

Participant flow — Overall Study
MilestonePRK CXLPTK CXLManual CXL
Started49149158
Completed49149158
Not completed000

Outcome measures

PrimaryVisual Acuity

Corrected Visual Acuity after crosslinking at the latest follow up examination

Time frame:
172 to 3396 days
Reported as:
Geometric mean · letters read per line
Visual Acuity
letters read per linePRK CXLPTK CXLManual CXL
Visual Acuity0.85 ± 0.330.83 ± 0.360.79 ± 0.35
PrimaryPostoperative K Max

K max after Crosslinking

Time frame:
172 to 3396 days
Reported as:
Mean · Diopters
Postoperative K Max
DioptersPRK CXLPTK CXLManual CXL
Postoperative K Max49.37 ± 4.5949.9 ± 4.8552.36 ± 5.05
PrimarySphere

Sphere values after crosslinking at lastest-follow-up

Time frame:
172 to 3396 days
Reported as:
Mean · Diopters
Sphere
DioptersPRK CXLPTK CXLManual CXL
Sphere0.5 ± 2.21-0.06 ± 2.72-0.87 ± 2.16
PrimaryCylinder

Refractive cylinder after Crosslinking at latest follow-up

Time frame:
172 to 3396 days
Reported as:
Mean · Diopters
Cylinder
DioptersPRK CXLPTK CXLManual CXL
Cylinder-1.5 ± 1.17-2.23 ± 1.92-2.16 ± 1.78
Other pre-specifiedEndothelial Cell Density

Endothelial cell density after Crosslinking at latest follow-up

Time frame:
172 to 3396 days
Reported as:
Mean · Cells/mm^2
Endothelial Cell Density
Cells/mm^2PRK CXLPTK CXLManual CXL
Endothelial Cell Density2886 ± 2642841 ± 3112786 ± 274

Adverse events

Collected over Up until 3 month post corneal crosslinking. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRK CXL0/33 (0%)0/33 (0%)6/33 (18.2%)
PTK CXL0/70 (0%)0/70 (0%)5/70 (7.1%)
Manual CXL0/20 (0%)0/20 (0%)0/20 (0%)
Most frequent other events
Most frequent other events
EventPRK CXLPTK CXLManual CXL
Sterile InfiltratesEye disorders6/335/700/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PRK CXLPTK CXLManual CXLTotal
<=18 years4243260
Between 18 and 65 years45125126296
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)PRK CXLPTK CXLManual CXLTotal
Female11323275
Male38117126281
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)PRK CXLPTK CXLManual CXLTotal
Count of participants———0
Corrected Visual Acuity
Corrected Visual Acuity(letters read per line)PRK CXLPTK CXLManual CXLTotal
Geometric mean0.7 ± 0.350.61 ± 0.350.41 ± 0.280.67 ± 0.36
Sphere
Sphere(Diopters)PRK CXLPTK CXLManual CXLTotal
Mean-0.29 ± 3.17-0.4 ± 3.48-1.95 ± 3.33-0.88 ± 4.38
Cylinder
Cylinder(Diopters)PRK CXLPTK CXLManual CXLTotal
Mean-2.96 ± 1.79-2.90 ± 2.28-2.04 ± 4.52-2.63 ± 3.12
Endothelial Cells
Endothelial Cells(cells/mm^2)PRK CXLPTK CXLManual CXLTotal
Mean2866 ± 2712796 ± 2842834 ± 3392818 ± 351
K1
K1(Diopters)PRK CXLPTK CXLManual CXLTotal
Mean45.11 ± 3.0244.29 ± 3.9349.7 ± 11.0944.81 ± 3.98

4 further baseline measures are reported on the registry.

08

Study locations

2 sites
09

References and documents

Publications

  • Koller T, Seiler T. [Therapeutic cross-linking of the cornea using riboflavin/UVA]. Klin Monbl Augenheilkd. 2007 Sep;224(9):700-6. doi: 10.1055/s-2007-963492. German. PubMed 17846959 ↗
  • Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007 May;26(4):385-9. doi: 10.1097/ICO.0b013e3180334f78. PubMed 17457183 ↗
  • Seiler T, Hafezi F. Corneal cross-linking-induced stromal demarcation line. Cornea. 2006 Oct;25(9):1057-9. doi: 10.1097/01.ico.0000225720.38748.58. PubMed 17133053 ↗
  • Wollensak G, Aurich H, Pham DT, Wirbelauer C. Hydration behavior of porcine cornea crosslinked with riboflavin and ultraviolet A. J Cataract Refract Surg. 2007 Mar;33(3):516-21. doi: 10.1016/j.jcrs.2006.11.015. PubMed 17321404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2007 to primary completion in Nov 2024, 204 months.

Results were first posted in Jun 2026, 1 year 7 months after primary completion.

Of 33 non-industry observational studies under Keratoconus, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 204. This study's 204 months is above that.

Counting every sponsor, half of 36 studies reached it within 30 months; a quarter within 13 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2007
First posted
Nov 20, 2007
StartActual
Nov 2007
Primary completionActual
Nov 2024
CompletionEst.
Nov 2027
Results first posted
Jun 18, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00560651
Lead sponsor
Suphi Taneri
Responsible party
Suphi Taneri (Director, St. Franziskus Hospital) — Sponsor-investigator
First posted
Nov 20, 2007
Start date
Nov 2007
Primary completion
Nov 2024
Completion
Nov 2027 (estimated)
Results posted
Jun 18, 2026
Last update
Jun 18, 2026

Study contacts

Suphi Taneri, MD
study chair · Augenklinik am St. Franziskus Hospital
Berthold Seitz, MD
study director · University of Homburg, Saar, Germany
Philip Maier, MD
study director · Univer. Freiburg, Germany
Claus Cursiefen, MD
study director · Univer. Erlangen, Germany
Thomas Reinhard, MD
principal investigator · Univers. Freiburg
Arnd Heiligenhaus, MD
principal investigator · Augenklinik am St.Franzsikus Hospital, Münster
Walter Sekundo, MD
principal investigator · Univers. Mainz
Theo Seiler, MD
principal investigator · IROC, Zürich
Atilla Osvald, MD
principal investigator · Univers Homurg, Saar
Jan M Vetter, MD
principal investigator · Univers. Mainz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion